NASDAQ: NAUT
Nautilus Biotechnology Inc Stock Forecast, Predictions & Price Target

Analyst price target for NAUT

Based on 1 analyst offering 12 month price targets for Nautilus Biotechnology Inc

Min Forecast
$4.00+348.93%
Avg Forecast
$4.00+348.93%
Max Forecast
$4.00+348.93%

Should I buy or sell NAUT stock?

Based on 1 analyst offering ratings for Nautilus Biotechnology Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NAUT's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates NAUT as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their NAUT stock forecasts and price targets.

NAUT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-27Find Out Why

1 of 1

Forecast return on equity

Is NAUT forecast to generate an efficient return?

Company
N/A
Industry
76.32%
Market
171.51%

Forecast return on assets

Is NAUT forecast to generate an efficient return on assets?

Company
N/A
Industry
38.75%

NAUT earnings per share forecast

What is NAUT's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.53
Avg 2 year Forecast
-$0.53
Avg 3 year Forecast
-$0.44

NAUT revenue forecast

What is NAUT's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$714.0k+275.79%
Avg 2 year Forecast
$7.8M+4,006.84%
Avg 3 year Forecast
$24.3M+12,676.84%
NAUT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NAUT revenue growth forecast

How is NAUT forecast to perform vs Biotechnology companies and vs the US market?

Company
389.61%
Industry
33.17%
Market
13.45%
NAUT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NAUT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NAUT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NAUT$0.89$4.00+348.93%Strong Buy
NTHI$4.35$16.00+267.82%Strong Buy
COYA$4.80$14.75+207.29%Strong Buy
CUE$28.24N/AN/A
GUTS$0.70$6.67+849.72%Strong Buy

Nautilus Biotechnology Stock Forecast FAQ

Is Nautilus Biotechnology Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: NAUT) stock is to Strong Buy NAUT stock.

Out of 1 analyst, 1 (100%) are recommending NAUT as a Strong Buy, 0 (0%) are recommending NAUT as a Buy, 0 (0%) are recommending NAUT as a Hold, 0 (0%) are recommending NAUT as a Sell, and 0 (0%) are recommending NAUT as a Strong Sell.

If you're new to stock investing, here's how to buy Nautilus Biotechnology stock.

What is NAUT's earnings growth forecast for 2026-2028?

(NASDAQ: NAUT) Nautilus Biotechnology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.88%.

Nautilus Biotechnology's earnings in 2026 is -$56,521,000.On average, 4 Wall Street analysts forecast NAUT's earnings for 2026 to be -$66,847,169, with the lowest NAUT earnings forecast at -$64,849,262, and the highest NAUT earnings forecast at -$68,145,172. On average, 4 Wall Street analysts forecast NAUT's earnings for 2027 to be -$67,496,170, with the lowest NAUT earnings forecast at -$76,073,172, and the highest NAUT earnings forecast at -$57,455,733.

In 2028, NAUT is forecast to generate -$55,814,141 in earnings, with the lowest earnings forecast at -$53,625,351 and the highest earnings forecast at -$57,455,733.

What is NAUT's revenue growth forecast for 2026-2028?

(NASDAQ: NAUT) Nautilus Biotechnology's forecast annual revenue growth rate of 389.61% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.45%.

Nautilus Biotechnology's revenue in 2026 is $190,000.On average, 4 Wall Street analysts forecast NAUT's revenue for 2026 to be $90,860,229, with the lowest NAUT revenue forecast at $62,355,059, and the highest NAUT revenue forecast at $120,256,186. On average, 4 Wall Street analysts forecast NAUT's revenue for 2027 to be $992,972,505, with the lowest NAUT revenue forecast at $598,608,569, and the highest NAUT revenue forecast at $1,402,988,834.

In 2028, NAUT is forecast to generate $3,089,247,794 in revenue, with the lowest revenue forecast at $2,968,100,821 and the highest revenue forecast at $3,180,108,023.

What is NAUT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: NAUT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 38.75%.

What is NAUT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year NAUT price target, the average NAUT price target is $4.00, with the highest NAUT stock price forecast at $4.00 and the lowest NAUT stock price forecast at $4.00.

The Wall Street analyst predicted that Nautilus Biotechnology's share price could reach $4.00 by Feb 27, 2027. The average Nautilus Biotechnology stock price prediction forecasts a potential upside of 348.93% from the current NAUT share price of $0.89.

What is NAUT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: NAUT) Nautilus Biotechnology's current Earnings Per Share (EPS) is -$0.45. On average, analysts forecast that NAUT's EPS will be -$0.53 for 2026, with the lowest EPS forecast at -$0.51, and the highest EPS forecast at -$0.54. On average, analysts forecast that NAUT's EPS will be -$0.53 for 2027, with the lowest EPS forecast at -$0.60, and the highest EPS forecast at -$0.45. In 2028, NAUT's EPS is forecast to hit -$0.44 (min: -$0.42, max: -$0.45).

What is NAUT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: NAUT) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.